Emerging Market Access Models Reshapes Drug Distribution

Prescription drug access in the United States has reached an inflection point. Pharmacy benefit managers (PBMs) have functioned mainly as claims processors and formulary administrators designed to help manage drug spending. However, their role has evolved into a dominant intermediary deciding coverage, pricing, and pharmacy reimbursement. This consolidation of influence has reshaped how medications are priced and distributed, often leaving patients, prescribers, and pharmacists with limited visibility into true drug costs.

Patients frequently discover out-of-pocket prices only at the pharmacy counter, and pharmacies receive reimbursement shaped by rebates and fee structures operating behind the scenes. These opaque mechanisms contribute to rising drug spending and unpredictable patient cost sharing. Concurrently, community pharmacies have experienced financial pressure. Declining margins, retroactive fees, and rising costs have challenged pharmacy sustainability and contributed to workforce strain and closures.

Price obscuration, reimbursement instability, and affordability challenges have placed the traditional PBM model under increasing scrutiny. Policymakers have responded with PBM transparency initiatives and reform proposals, recognizing that the legacy model may no longer meet patient and pharmacy needs.

The Traditional PBM-Centered Pharmacy System

Under the traditional United States prescription drug model, PBMs sit at the intersection of manufacturers, insurers, pharmacies, and patients. When a prescription is filled, the pharmacy submits an electronic claim that is adjudicated in real time by a PBM, which determines coverage, the patient’s cost-sharing, and the pharmacy reimbursement.

PBMs exert influence through formulary design, rebate negotiations, pharmacy network participation, and reimbursement strategies that often operate with limited transparency, making it challenging for prescribers and patients to anticipate out-of-pocket costs.

This opacity becomes most visible at the pharmacy counter, where unexpected costs contribute to prescription abandonment. Meanwhile, declining reimbursement and retroactive fees continue to strain pharmacy sustainability, particularly for independent and rural locations.

Why Alternative Pharmacy Channels Emerged

Unpredictable out-of-pocket costs created an opportunity for models offering price visibility prior to dispensing. High deductibles, variable copays, and limited cost transparency at the point of prescribing have led patients to delay or abandon therapy, and digital platforms enabled real-time price comparison and centralized fulfillment at scale.

GoodRx, Cost Plus Drugs, and Amazon Pharmacy illustrate how prescription access is being redesigned.

GoodRx: Price Transparency Without Replacing Retail Pharmacies

GoodRx focuses on price visibility rather than dispensing. The platform allows patients to compare cash prices across retail pharmacies before filling a prescription, addressing the frustration of discovering true out-of-pocket costs only at checkout. Transactions are processed as cash-pay claims through PBM-linked discount networks, while still relying on retail pharmacies for fulfillment. For uninsured patients and those with high-deductible plans, this can result in lower prices for common generics. However, these savings often come at the expense of pharmacy margins, as discount card transactions are associated with lower reimbursement and added fees, creating ongoing tension for community pharmacies.

Mark Cuban Cost Plus Drugs: Transparent Pricing and Centralized Fulfillment

Mark Cuban Cost Plus Drug Company rebuilds pricing and fulfillment. Medications are priced at acquisition cost plus a fixed markup and dispensing fee, eliminating rebates, spread pricing, and retroactive adjustments. Prescriptions are filled through centralized mail-order pharmacies and shipped directly to patients, reducing overhead and lowering costs for many generics. Because the model operates exclusively on a cash-pay basis and focuses on generics, it does not integrate with insurance benefits or address brand and specialty drug access.

Amazon Pharmacy: Industrializing Prescription Distribution

Amazon Pharmacy emphasizes distribution efficiency. By integrating insurance-based claims, cash-pay options, centralized fulfillment, and home delivery within a single platform, Amazon industrializes prescription dispensing. This approach improves convenience and adherence for maintenance medications while competing directly with retail pharmacies for prescription volume.

What This Means for Retail Pharmacies

Retail pharmacies are increasingly experiencing financial, operational, and structural pressures from evolving access models and alternative distribution channels. Rising out-of-pocket costs and high-deductible insurance plans have encouraged patients to seek lower-cost alternatives, contributing to shrinking profit margins and shifting prescription volume away from traditional storefront dispensing.

Independent pharmacies demonstrate higher turnover than chain pharmacies, suggesting they are being affected more by ongoing economic and structural shifts within the prescription drug market. Patients increasingly must choose between insurance and cash-pay alternatives at dispensing. Cost-related medication nonadherence remains prevalent, with many adults reporting delayed refills, skipped doses, or unfilled prescriptions due to unexpected out-of-pocket costs.

In response to declining dispensing margins, retail pharmacies have expanded clinical and service-based revenue models, including immunizations, medication therapy management, chronic disease management, and point-of-care testing.

Regulatory and Legal Implications

Evolving channels pose legal and regulatory challenges, including licensure, supply chain integrity, consumer protection, data security, and professional risk.

Mail-order fulfillment also raises drug integrity considerations, including licensure, transaction documentation, product traceability, controlled substance monitoring, and delivery security.

As telehealth, digital prescribing, and direct-to-consumer fulfillment expand, pharmacies must maintain robust cybersecurity protections and comply with privacy requirements.

Conclusion

Emerging market access models have moved away from traditional PBM-centered pharmacies, improving patient adherence through convenience and guidance around cost barriers with platforms such as GoodRx, Cost Plus Drugs, and Amazon Pharmacy. However, retail and frontline pharmacies are increasingly impacted by declining profit margins, with pharmacy closures contributing to greater reliance on clinical service-based models. As new channels emerge, pharmacists must address new challenges, including maintaining drug integrity and implementing adequate cybersecurity to protect patient privacy and safety.